NSCLC (ROS1-Rearranged) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About NSCLC (ROS1-Rearranged)
Non-Small Cell Lung Cancer (NSCLC) with a ROS1 rearrangement is a distinct form of lung cancer, treatable with specific targeted therapies. While these advanced medications offer significant hope, their cost can be a major hurdle. TheDrugClub helps individuals and families access these vital prescriptions at a more affordable price, easing the financial burden during treatment.
Non-Small Cell Lung Cancer (NSCLC) accounts for the vast majority of lung cancer diagnoses. Within this broad category, scientists have identified various genetic mutations that drive cancer growth. One such specific alteration is the ROS1 rearrangement, found in a small percentage (typically 1-2%) of NSCLC patients. This rearrangement involves an abnormal fusion of the ROS1 gene with another gene, leading to the production of a faulty protein that promotes uncontrolled cell growth. Identifying a ROS1 rearrangement is crucial because it means the cancer is "actionable" – it can be effectively targeted by specific medications, offering a personalized treatment pathway that differs from standard chemotherapy.
Diagnosis of ROS1-positive NSCLC usually involves molecular testing of tumor tissue obtained through biopsy, or sometimes through a liquid biopsy using a blood sample. This testing helps oncologists determine the most effective course of treatment. For patients with ROS1-rearranged NSCLC, the primary treatment approach involves targeted therapies. These oral medications are designed to specifically block the activity of the abnormal ROS1 protein, thereby inhibiting cancer cell growth. Examples of common medications include crizotinib (brand name Xalkori), entrectinib (Rozlytrek), and lorlatinib (Lorbrena). While these drugs have significantly improved outcomes for many patients, they are often specialty medications, meaning they come with a high price tag, potentially costing thousands of dollars per month.
This is where TheDrugClub steps in to make a real difference. Our prescription savings membership program is designed to help you afford the medications you need, including expensive specialty drugs for conditions like ROS1-positive NSCLC. For a low monthly fee – with a Drug Club membership – members gain access to discounted prices on thousands of prescription medications. The
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.